Second-line Treatment for RS-negative Lower-Risk MDS: Choosing Between EMA and Telomerase Inhibitor Options
Dr Sekeres shares his thoughts about the choice between an EMA and a telomerase inhibitor in the RS-negative patient.
EP: 1.Anemia in Lower-Risk MDS: Introduction and Case Presentation
EP: 2.Lower-Risk MDS: Frontline Therapy Initiation and Determination of Treatment Failure
EP: 3.Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Imetelstat
EP: 4.Patient Treatment Goals for Lower-Risk MDS
EP: 5.Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Luspatercept
EP: 6.Optimizing Anemia Management in Lower-Risk MDS: Key Takeaways
EP: 7.Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Lenalidomide
EP: 8.Second-line Treatment for RS-negative Lower-Risk MDS: Choosing Between EMA and Telomerase Inhibitor Options
EP: 9.Adverse Event Profile and Management of Imetelstat
With the advent of new options for treatment after ESAs for patients with LR-MDS, please share your thoughts about the choice between an EMA and a telomerase inhibitor in the RS-negative patient.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
